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ABSTRACT 
Erlotinib hydrochloride (Tarceva) is a targeted cancer therapy drug approved for treatment 
of non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. An 
efficient and economical synthetic method of title compound from ethyl 3,4-dihydroxybenzoate 
is described in 6 steps with overall yield of 51 %. 
Keywords: Erlotinib, non small cell lung cancer, synthesis.  
1. INTRODUCTION 
Erlotinib was discovered in the early 1990s as a selective inhibitor of the epidermal growth 
factor receptor (EGFR, IC50 = 2 nm) by binding specifically to ATP of EGFR tyrosine kinase 
intracellular [1]. The EGFR overexpression often leads to the formation and growth of solid 
tumors, especially in the lungs, including 40 – 80 % of non-small cell lung cancer cases. It 
involves the development of tumors, proliferation, apoptosis, metastasis, and angiogenesis [2]. 
EGFR also protects cells from the malignant tumor cytotoxic effects of chemotherapy and 
radiotherapy, which makes therapeutic effect of this approach significantly reduced. 
Erlotinib (Figure 1) is approved by US FDA for the treatment of locally advanced or 
metastatic non-small cell lung cancer that has failed at least one prior chemotherapy regimen. 
For pancreatic cancer, erlotinib is used in combination with gemcitabine in all stages [3]. Studies 
have shown that the using erlotinib in combination with chemotherapy can increase survival 
rates to over 19 % [4]. As a moleculary targeted cancer therapy drug, erlotinib has few side 
effects and helps to relieve pain and cough, so improves the quality of patient life. 
We reported herein an efficient and economical approach for the preparation of erlotinib 
hydrochloride from the readily available starting materials in Vietnam, which can be scale up to 
provide drug raw materials for Vietnam Pharmaceutical Industry. 
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Figure 1. Chemical structure of erlotinib hydrochloride (1). 
2. EXPERIMENTAL 
All reagents and solvents were purchased from Sigma-Aldrich, Acros and Merck and used 
withoutpre-purification. Silica gel for column chromatography (0.040 – 0.063 mm) and thin 
layer chromatographywere purchased from Merck (Germany). NMR spectra were recorded on a 
Bruker Avance 500 (Germany) spectrometer using TMS as internal standard. Chemical shifts 
were reported in parts per million (ppm)downfield from internal tetramethylsilane (TMS). MS 
spectra and HPLC were recorded on aLC_MS Agilent 1100 (USA). All reactionswere monitored 
by thin layer chromatography (TLC) using silica gel 60 coated plates F254 (aluminum sheets). 
Visualization was performed by UV at 254 and 354 nm. 
Ethyl 3,4-bis(2-methoxyethoxy)benzoate (3): A mixture ofethyl 3,4-dihydroxybenzoate 
(1.0 g; 5.5 mmol) (2), K2CO3 (1.82 g, 13.0 mmol) in DMF (10 mL) was heated and stirred at 100 
°C for 1 h. After cooling of the reactional mixture to 50 °C, 1-methoxy-2-bromoethane (1 mL) 
was addedandheatedat 80 °C for 2 h.The resulted mixture was cooled to room temperature, 
filtredand washedthe solid with ethyl acetate(10 mL).  Organic layers were combined, driedover 
Na2SO4 and concentrated under reduced pressure to afford a yellow solid (3, 94.3 %). 1H-NMR 
(500 MHz, CDCl3)δ (ppm): 1.37 (t, 3H, CH3-CH2,J = 7.0 Hz), 3.45 (s, 3H, CH3O), 3.46 (s, 3H, 
CH3O),3.80 (m, 4H, 2x CH3OCH2), 4.20 (m, 4H, 2x CH3OCH2CH2O), 4.34 (q, 2H, CH3CH2, J = 
7.0 Hz),6.90 (d, 1H, J = 8.5 Hz, H-5), 7.58 (d, 1H, J = 2.0 Hz, H-2),7.66 (dd, 1H, J = 8.5 & 2.0 
Hz, H-6). 
Ethyl 4,5-bis(2-methoxyethoxy)-2-nitrobenzoate (4): HNO3conc.(4.5 mL) was added 
drop wise to a solution of 3(500 mg, 2.0 mmol) in CH3COOH (1.9 mL)at 0 – 5 °C and stirred at 
room temperature for  24 h.The mixture was poured in to the ice water and ethyl acetate was 
added. Organic layer was washed with saturated NaHCO3 solution, dried over Na2SO4and 
concentrated  under reduced pressure to yield a yellow liquid (90.7 %).1H-NMR (500 MHz, 
CDCl3)δ (ppm) : 1.34 (t, 3H, CH3CH2, J = 7.0 Hz), 3.44 (s, 6H, 2xOCH3), 3.79 (m, 4H, 
2xCH3OCH2), 4.24 (m, 4H, 2x CH2O), 4.36 (q, 2H, CH2CH3,J = 7.0 Hz),  7.12 (s, 1H, H-3), 
7.50 (s, 1H, H-6). 
Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate (5): propan-2-ol (1.59 mL) was added 
in to a flask containing Pd/C 10 % (45 mg). Solution of ammonium formate (0.265 g) in water 
(0.2 mL)was added to the flask and the mixture was stirred at room temperature for 1 min to 
activate Pd.Then 4 (0.15 g, 0.41 mmol) was added to the reactional mixture and continue to stir 
at room temperature for 20 min.The resulted mixture was filtred and washed with ethyl acetate 
and propan-2-ol. The filtrate was concentrated under reduced pressure to give a residue which 
was extracted with ethyl acetate, dried over Na2SO4, to obtain 5(95.1 %).1H-NMR (500 MHz, 
CDCl3)δ (ppm): 1.36 (t, 3H, CH3, J = 7.0 Hz), 3.44 (2s, 6H, 2xCH3),  3.72 &3.77 (2t, 2x2H, 
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2xOCH2, J = 5.0 Hz),4.09 & 4.14 (2t, 2x2H, 2CH2O, J = 5.0 Hz),4.30 (q, 2H, CH2CH3, J = 7.0 
Hz), 6.30 (s, 1H, H-6), 7.46 (s, 1H, H-3).13C-NMR(125 MHz, CDCl3) δ (ppm): 166.9 (C=O), 
150.1 (C-5), 141.2 (C-7),133.6 (C-4), 116.5 (C-3), 108.8 (C-2), 101.2 (C-6), 77.3 (C-18, C-18’), 
74.1 (C-17, C-17’), 60.9 (C-19, C-19’), 52.5 (CH2-CH3), 18.5 (CH2-CH3). 
6,7-bis(2-methoxyethoxy)-4-quinazolone (6): Amine 5(0.55 g, 1.75 mmol) and 
HCOONH4 (0.11 g, 1.75 mmol) were disolved in H2N-CHO (0.83 mL).  The mixture was stirred 
and heated at 160 °C for 1,5 h under inert atmosphere. Cold water was added and forming 
precipitates were filtred,  washed by cold water and dried.  The filtrate was extracted with 
chloroform and the organic layer was washed with brine, dried over Na2SO4 and  concentrated 
under reduced pressure. The precipitates and chloroform residue were combined, treated with 
diethyl ether and filtred to afforded 6(79.6 %). 1H-NMR (500 MHz, CDCl3)δ (ppm): 3.50 (s, 
6H, 2 xOCH3), 3.87 (m, 4H, 2xOCH2), 4.30 (m, 4H, 2xCH2O), 7.17 (s, 1H, H-6), 7.62 (s, 1H, H-
3),8.04 (s, 1H, H-8), 11.72 (s, 1H, NH). 13C-NMR(125 MHz, CDCl3)δ (ppm): 162.3 (C=O), 
155.0 (C-5),  148.9 (C-8),145.4 (C-7),142.3 (C-4),115.9 (C-3), 109.4 (C-2),106.8 (C-6),70.7& 
70.5 (C-18, C-18‘),68.7& 68.6 (C-17, C-17‘),59.3(C-19, C-19‘). ESI-MS: [M+H]+295.11. 
4-chloro-6,7-bis(2-methoxyethoxy)quinazolin (7): Dimethylammoniumpyridine (42 mg, 
0.34 mmol) and POCl3 (0.32 mL) were added to a flask containing quinazolone 6 (0.1 g, 0.34 
mmol) in tolunene (5 mL) at room temperature. The mixture was heated at 90 °C for 20 min then 
maintained at 85 °C for 30 min. When the reaction finished (monitored by TLC), POCl3 was 
eliminated by evaporator under reduced pressure. The residue was diluted with toluene (3×50 
mL), poured in to ice water and extracted with ethyl acetate (4×50 mL). Organic layers were 
combined, dried over Na2SO4, evaporated of solvents to result a white solide (90.3 %).1H-NMR 
(500 MHz, CDCl3) δ (ppm): 3.49&3.50 (2s, 2x3H, 2xOCH3), 3.88-3.90 (m, 4H, OCH2), 4.34-
4.38 (m, 4H, CH2O), 7.47 (s, 1H, H-3), 7,51 (s,1H, H-6), 8.9 (s, 1H, H-8). 13C-NMR(125 MHz, 
CDCl3) δ (ppm): 159.8 (C-5), 157.0 (C-1), 151.6 (C-8), 151.4 (C-4), 147.7 (C-7), 119.7 (C-2), 
106.9 (C-6), 104.3 (C-3), 70.6 &70.3 (C-18, C-18’), 69.1 & 69.0 (C-17, C-17’), 59.4 (C-19, C-
19’). 
Erlotinib hydrochloride (1) : Quinazoline 7 (0.17 g, 0.54 mmol) in H2O (2.61 mL) and 3-
ethynylaniline (0.07 mL) were added in to a flask. The mixture was heated at 30 °C and a 
solution HCl conc. (0.05 mL) was added. The mixture was maintained at 40 °C for 1 h.  After 
cooling, the solid was separated by filtration, washed with water and ether, then dried at 40°C to 
obtain a white solid 1(87.5 %). 1H-NMR (500 MHz,DMSO-d6) δ (ppm):3.35 & 3.36 (2s, 2x3H, 
2xOCH3), 3.74-3.79 (m, 4H, 2xOCH2), 4.18 (s, 1H, ≡CH), 4.28-4.32 (m, 4H, 2xCH2O), 7.20 (d, 
1H, J = 8,0 Hz, H-12),7.23 (s, 1H, H-6), 7,40 (t, 1H, J = 8.0 Hz, H-11), 7.90-7.92 (m, 2H, H-10, 
H-3), 8.01 (s, 1H, H-14),8.49 (s, 1H, H-8),9.8 (br, 1H, NH). 13C-NMR (125 MHz, DMSO-d6) δ 
(ppm):156.2 (C-1), 153.6 (C-5), 152.7 (C-8), 148.1 (C-4), 147.0 (C-7), 139.9 (C-9),128.8 (C-
11), 126.2 (C-12), 124.8 (C-14), 122.6 (C-10), 121.6 (C-13), 109.0 (C-2), 108.2 (C-6), 103.5 (C-
3), 83.5 (C-15), 80.4 (C-16), 70.1 & 70.0 (C-18, C-18‘),68.0 (C-17, C-17‘), 58.3 (C-19, C-19‘). 
ESI-MS [M+H]+394.34 (tính toán 394.44). 
3. RESULTS AND DISCUSSION 
The reported synthesis methods of erlotinib often start from3,4-hydroxy-benzaldehyde, 3,4-
hydroxybenzoic acid or ethyl 3,4-hydroxybenzoate [5 - 9]. But by using the staring material as 
aldehyde we have received the low yield and the product purification was difficult due to the 
many byproducts. By combining the method of  Reddy [6], Knesl [7] and Barghi [9], we have 
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prepared erlotinib hydrochloride according to the process including six steps from the ethyl 3-4-
hydroxy benzoate(Figure 2). 
 
Figure2. Synthetic pathway of  erlotinib hydrochloride (1): a) CH3OCH2CH2Br, K2CO3, DMF, 100°C, 
2h. b) CH3COOH, HNO3, 5°C, 30  min. c) propanol-2, ammonium formate, Pd/C, 25 0C. d) ammonium 
formate, formamide, 160°C, 8h, e) POCl3, DMAP, 80-90 0C. f) H2O, HCl, m-ethynylaniline, 40 0C. 
The O-alkylation of esters 2 with 1-bromo-2-methoxyethane in DMF and K2CO3as 
catalysts at 100 0C afforded 3 with high yield. Adding a phase transfer catalyst as TBAC 
(tetrabutyl ammonium chloride) does not help to improve the yield of the reaction. Nitration of 
compound 3 in nitric acid and glacial acetic acid give only derivatives 4 in 90.7 % yield. The 
structure of 4 was determined by 1H-NMR and compared to the reported  data [7]. Reduction of 
nitro groups was carried out at room temperature with catalytic Pd/C10% and ammonium 
formate, gave amine 5 with high yield (95 %). 
The synthetic pathway from 2-5 can be done directly on the crude products without 
purification by silica gel column, while avoiding the use of flammable and explosive hydrogen 
gas. Cyclization occured in formamide in the presence of ammonium formate (6, 79.6 %). 1H 
and  13C NMR spectra of  6 confirmed the quinazolone structure with one more insaturated CH 
group (1 singlet at δH 8.04 ppm,and δC 148.9 ppm) and a shifting to higher field of carbon C = O 
signal, compared with the spectra of  5. The molecular ion peaks from ESI-MS spectrum of 6 
was matched with the calculated mass ([M+H]+m/z 295,11, calculated 295.13) and 
corresponding to the loss of 1 and 2 methoxyethyl group (m/z 237.07 and 178.99).  
For the preparation of  4-chloro-derivatives quinazoline 7, oxalylchloride and POCl3 were 
used as clorination reagent. When using POCl3, higher reaction yield was obtained comparing to 
the reaction using oxalylchloride even in large excess of reagent. In the final step, erlotinib was 
prepared by the substitution of ethynyl aniline in acidic medium, so the product is obtained 
under hydrochloride salt form as white crystals (1, 87.5 %). The overall yield of erlotinib 
hydrochloride preparation was 51 % with 6 steps. Chemical structure of compound 1 was 
determined by NMR (1, 2D) and MS spectra. NMR spectra of 1 showed the presence of the 
quinazoline ring signals together with aromatic ring signals owning 3 protons and acetylyl group 
(1 singlet of CH at δH 4.18 ppm (Figure 3)2 carbon at δC 83.5 ppm and 80.4 ppm). (+) - ESI-MS 
spectrum (Figure 4) gave molecular ion peak [M+H]+at m/z 394.34, including ion peaks 
corresponding to the loss of one MeO-C2H3 group at m/z 336.25 [(M+H)-C3H6O]+, or two MeO-
  
Preparation of  Erlotinib hydrochloride 
 
793 
C2H3 groups at m/z 278.03 [(M+H)-2C3H6O]+. HPLC analysis (Figure 5) showed that the 
synthetic erlotinib hydrochloride had 99.5 % purity. 
 
Figure 3.1H NMR spectrum of erlotinib hydrochloride (1) (500 MHz, DMSO d6). 
 
Figure 4. (+) ESI-MS spectrum của erlotinib hydrochloride (1). 
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Figure5. HPLC chromatogramoferlotinib hydrochloride (1). 
4. CONCLUSIONS 
Erlotinib hydrochloride was prepared by an efficient and economical process in 6 stepswith 
overall yield of 51 %. The products from each stepcan be used as crude form without 
purification by silica gel chromatography for the next step.The synthetic process can be scaled 
up for the trial production. 
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TÓM TẮT 
NGHIÊN CỨU TỔNG HỢP ERLOTINIB HYDROCHLORIDE 
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Erlotinib hydrochloride (Tarceva) là một thuốc điều trị trúng đích được dùng cho điều trị 
ung thư phổi dạng tế bào không nhỏ, ung thư tụy và một số loại ung thư khác. Trong bài báo 
này, erlotinib hydrochloride đã được nghiên cứu tổng hợp theo một phương pháp đơn giản, hiệu 
quả  bao gồm 6 giai đoạn phản ứng, với hiệu suất tổng thể  là 51 %. 
Từ khóa: Erlotinib, ung thư phổi, phương pháp tổng hợp.  
 
 
 
